drugset

drugset / Trial / NCT04151667

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667 ↗

Phase 2 Active not recruiting 33 enrolled H. Lee Moffitt Cancer Center and Research Institute Janssen Scientific Affairs, LLC · collab

Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.

Timeline

Start: 2019-11-22
Primary completion: 2023-11-08
Completion: 2026-05-07

Publications

Meads MB, Zhao X, Noyes D, Sudalagunta PR, Achille A, Zhang C, Canevarolo RR, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil SS, Yoder SJ, Grajales-Cruz AF, Blue B, Freeman CL, Kim J, Alsina M, Brayer J, Silva AS, Song X, Shain KH, Baz R. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2026 Jan 29;147(5):497-512. doi: 10.1182/blood.2025029921.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Subcutaneous
Subject	Daratumumab	Monoclonal antibody	1800 mg	Subcutaneous
Subject	Lenalidomide	Other / unclassified	10 mg	Oral
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Background	Dexamethasone	Small molecule	20 mg	Oral

Indications